HBsAg阳性转基因小鼠肝脏中昼夜节律基因dbp转录水平变化的研究

目的 验证HBsAg阳性转基因小鼠肝脏中昼夜节律表达基因dbp (coding for the D site albumin promoter binding protein)转录水平的变化。 方法 用实时荧光定量聚合酶链式反应方法对比研究雌、雄及个体HBsAg阳性转基因小鼠及对照鼠肝脏dbp转录水平的变化。研究不同时间点HBsAg阳性转基因小鼠及对照鼠肝脏dbp转录水平的变化。 结果 #59 及#10 品系组HBsAg阳性转基因小鼠肝组织中dbp均较对照组动物上调, 但个体间差别较大。初步结果显示雌性正常小鼠dbp转录水平较雄性为高。而在雌性HBsAg阳性转基因小鼠中dbp的上调进一步增强。与此相反,雄性转基因小鼠dbp的上调则较同性对照鼠更弱。转基因小鼠dbp转录,在8：00时及14：00时平均水平均高于对照鼠,然而在20：00时及2：00时则与对照鼠相当。结论 本研究首次报道HBsAg阳性转基因小鼠肝脏中dbp表达的上调,提供了乙型肝炎病毒蛋白表达与昼夜节律基因变化有所联系的证据。至于本研究在转基因鼠中的发现是否在乙型肝炎患者中存在及其意义还有待在患者中作进一步临床验证与研究。     

乙型肝炎表面抗原阳性转基因小鼠肝组织基因表达谱及蛋白组学的初步研究

目的 利用与乙型肝炎病毒(ItBV)携带者相类似的#59系HBV转基因小鼠动物模型研究乙型肝炎表面抗原(HBsAg)蛋白对肝组织生理、代谢状态的影响,以了解HBsAg持续表达对肝细胞影响的机制。方法 用Affmertix基因芯片观察转基因小鼠肝组织基因表达谱的改变。用蛋白组学方法鉴定部分代谢相关酶类在转基因小鼠肝组织内的丰度改变。结果 基因芯片实验显示43个基因在转基因小鼠肝组织内显著(≥2倍)上调表达,104个基因显著下调表达。蛋白组学实验检出18个代谢相关酶在转基因小鼠肝组织内丰度高于对照鼠1．5倍以上,9个代谢相关酶低于对照鼠1．5倍以上。结论 HBV蛋白的存在对宿主肝组织代谢状态产生显著影响。推测其表现为胆固醇合成增强、胆汁酸合成减弱。糖异生作用增强、糖酵解减弱。氨基酸分解代谢增强、尿素合成减弱。     

p21HBsAg/HBsAg转基因小鼠肝癌发生过程中PCNA的表达及意义

[目的]探讨乙型肝炎病毒表面抗原定位整合(p21HBsAg/HbsAg)转基因小鼠肝癌发生过程中PCNA的表达及意义。[方法]分别选取2,6,12,18,24月龄的SPF级转基因小鼠,取肝脏及肝脏肿瘤组织,进行免疫组织化学S-P法染色。[结果]①阳性肝细胞核内可见棕黄色反应颗粒;②2,6月龄转基因小鼠肝脏有少量散在分布的肝细胞呈PCNA阳性表达,阳性率分别为2.5%,3%;12月龄转基因小鼠肝脏PCNA阳性表达主要出现在非典型增生的肝细胞,阳性率23.65%;18月龄转基因小鼠发生的肝细胞癌PCNA阳性率61.68%;24月龄的转基因小鼠发生的肝细胞癌PCNA阳性率63.56%。12月龄转基因小鼠PCNA阳性率高于2,6月龄转基因小鼠(p<0.01),18月龄和24月龄的转基因小鼠PCNA阳性率高于12月龄转基因小鼠(p<0.05)。[结论]①PCNA能准确反映乙型肝炎病毒表面抗原定位整合转基因小鼠肝细胞的增殖能力,PCNA与肝细胞癌的发生、发展密切相关;②非典型增生的肝细胞有较高的PCNA阳性表达,是一群具有肿瘤增殖潜能的癌前细胞群。     

构建LEF1基因毛囊特异表达载体并稳定转染胎儿成纤维细胞

旨在构建内蒙古白绒山羊(Capra hircus)淋巴样增强因子-1(Lymphoid enhancer factor,LEF1)基因真核表达载体并转染胎儿成纤维细胞,获得稳定表达红色荧光蛋白及毛囊特异性表达LEF1的转基因细胞克隆。以pCDsRed2载体为基本骨架将LEF1基因亚克隆到KAP6-1启动子下游,连接红色荧光蛋白表达元件,构建LEF1基因毛囊特异表达载体pCDsRed-KL。外源表达载体以lipofectamineTM2000介导转染胎儿成纤维细胞,通过G418筛选获得稳定转染的细胞克隆。PCR鉴定外源基因在细胞基因组中的整合。测序显示构建的表达载体pCDsRed-KL序列中,LEF1基因正确连接在KAP6-1启动子下游,顺序连接CMV启动子和红色荧光蛋白基因,载体构建正确。脂质体介导的稳定转染效率约为14.0%,经G418筛选得到高效表达红色荧光蛋白转基因细胞克隆。PCR检测显示外源KAP6-1启动子和LEF1基因整合到胎儿成纤维细胞基因组中。     

人β_2m转基因小鼠的制备及鉴定(英文)

制备人 β2m转基因小鼠 ,研究HLA B2 70 4基因的表达 .应用显微注射将人 β2m基因注入C5 7BL 6×昆明鼠和昆明鼠×昆明鼠F1代受精卵 .出生动物及其后代经PCR筛选 ,采用斑点杂交和Southern杂交对阳性鼠基因组DNA标本进行进一步鉴定和测定整合拷贝数 ,利用RT PCR检测阳性鼠中人 β2m转基因的表达 .6只原代仔鼠及 7只它们的下一代鼠 (F1)带有人 β2m基因 .由微注射基因后移卵出生的 86只小鼠中 ,C5 7BL 6×昆明鼠杂交仔鼠 35只 ,其中 4只阳性 (11 4 % ) ,昆明鼠×昆明鼠杂交仔鼠 5 1只 ,其中 2只阳性 (3 9% ) ,含有人 β2m基因的原代鼠×昆明鼠杂交仔鼠 2 0只 ,其中 7只阳性 .整合的转基因均为单拷贝 .Southern杂交证实上述阳性鼠确有转基因整合 .阳性鼠的皮肤、结肠、睾丸和脾脏组织中均有人β2m转基因mRNA的表达 .在转基因动物制备中 ,C5 7BL 6×昆明鼠F1代明显优于昆明鼠×昆明鼠F1代 .与人HLA B2 70 4基因相比 ,人 β2m基因不易整合 ,其整合率与整合拷贝数均较低 .得到的人 β2m转基因小鼠能够将人 β2m基困传给下一代 ,并可与人HLA B2 70 4转基因鼠交配 ,研究它的致病性     

人β_2m转基因小鼠的制备及鉴定(英文)

 制备人 β2m转基因小鼠 ,研究HLA B2 70 4基因的表达 .应用显微注射将人 β2m基因注入C5 7BL 6×昆明鼠和昆明鼠×昆明鼠F1代受精卵 .出生动物及其后代经PCR筛选 ,采用斑点杂交和Southern杂交对阳性鼠基因组DNA标本进行进一步鉴定和测定整合拷贝数 ,利用RT PCR检测阳性鼠中人 β2m转基因的表达 .6只原代仔鼠及 7只它们的下一代鼠 (F1)带有人 β2m基因 .由微注射基因后移卵出生的 86只小鼠中 ,C5 7BL 6×昆明鼠杂交仔鼠 35只 ,其中 4只阳性 (11 4 % ) ,昆明鼠×昆明鼠杂交仔鼠 5 1只 ,其中 2只阳性 (3 9% ) ,含有人 β2m基因的原代鼠×昆明鼠杂交仔鼠 2 0只 ,其中 7只阳性 .整合的转基因均为单拷贝 .Southern杂交证实上述阳性鼠确有转基因整合 .阳性鼠的皮肤、结肠、睾丸和脾脏组织中均有人β2m转基因mRNA的表达 .在转基因动物制备中 ,C5 7BL 6×昆明鼠F1代明显优于昆明鼠×昆明鼠F1代 .与人HLA B2 70 4基因相比 ,人 β2m基因不易整合 ,其整合率与整合拷贝数均较低 .得到的人 β2m转基因小鼠能够将人 β2m基困传给下一代 ,并可与人HLA B2 70 4转基因鼠交配 ,研究它的致病性     

可调控肝脏特异性表达HCV全基因转基因小鼠模型的建立

目的:构建一种可调控肝细胞特异性表达丙型肝炎病毒(HCV)全基因的小动物模型。方法:将9.6 kb的HCV全长基因JFH1插入Tet-on系统效应表达载体p TRE2中,并在HCV全基因3'端插入丁型肝炎病毒(HDV)核酶序列,从而构建转基因载体p TRE2-JFH1(HCV);将该转基因载体线性化后显微注射获得整合有HCV全基因的TRE2-HCV首建鼠;将该阳性鼠与本室保存的Alb-rt TA转基因小鼠杂交,获得肝细胞白蛋白启动子调控HCV全基因表达的Tet-on-Alb-HCV双转基因小鼠;在强力霉素(Dox)诱导后通过PCR、Western印迹、免疫组化等方法鉴定转基因小鼠HCV基因整合及HCV蛋白在肝组织中的表达;实时定量PCR检测小鼠血清及肝组织中的HCV滴度;用HCV反义小分子药物anti-mi R122评价该模型在药物评价中的应用。结果:获得了整合rt TA基因和HCV全长基因的双转基因小鼠;Dox诱导下,该转基因小鼠可在肝组织长期特异性表达HCV全长基因,小鼠血清中可检测到HCV的RNA;分子药物anti-mi R122可降低血清中的HCV滴度。结论:构建了可调控肝组织特异性表达HCV全基因的转基因小鼠模型,该小鼠模型可应用于HCV药物筛选和评价研究。     

人肾素转基因小鼠的建立

为研究人肾素基因在体内的功能和建立其药物干预实验的动物模型,采用显微注射法,将纯化的人肾素基因导入小鼠受精卵,再培育成转基因小鼠.通过DIG DNA印迹和PCR分析,进行转基因整合检测.在出生的13只子代鼠中,得到一只转基因阳性鼠.整合率为7.7%,有效率0.3%,转基因已稳定传代.RT-PCR显示转基因阳性鼠的肾、心和肺组织中有肾素基因表达,而在肝脏与骨骼肌中则未检测到.阳性鼠血浆肾素活性较对照鼠明显升高,而肾与心脏组织的肾素活性则无明显变化.人肾素转基因小鼠可用于研究循环或组织的RAS中肾素基因的功能及有关其药物抑制实验.     

肝细胞中活化转录因子ATF6抑制SREBP1的转录活性

内质网膜定位的活化转录因子ATF6和SREBP1均是经过蛋白酶切水解激活,激活后的ATF6(N)和SREBP1(N)进入细胞核内,分别指导内质网膜未折叠蛋白聚集反应相关基因和脂肪酸合成相关基因的表达.研究发现,肝细胞内葡萄糖饥饿激活ATF6并抑制SREBP1的转录活性及其靶基因的表达.过表达ATF6(N)能够抑制SREBP1介导的转录及其下游基因的表达.免疫共沉淀实验显示,ATF6(N)在细胞核内结合SREBP1(N),这种结合在无糖状况下增强.不同功能区缺失分析表明,ATF6和SREBP1通过亮氨酸拉链(leucinezipper)功能区相互作用.在葡萄糖饥饿状况下,ATF6对SREBP1转录活性的抑制保证了细胞基本生命活动所需要的能量.     

Dicer1转基因小鼠模型的建立

目的建立Dicer1转基因小鼠模型。方法构建pcDNA3.1-Dicer1转基因构件,经酶切、纯化后通过显微注射方法导入BDF1小鼠受精卵原核并移植到同期受孕的ICR受体母鼠输卵管内。出生后仔鼠用PCR和Southern方法检测鼠尾DNA鉴定基因型,通过免疫组化检测Dicer1基因表达。结果显微注射172枚卵,移植119枚卵于3只受体输卵管中,2只怀孕,共产仔15只,经PCR检测获得6只阳性鼠,Southern检测6只均为阳性。对Southern检测阳性转基因小鼠子代进行RT-PCR检测和免疫组化分析证明Dicer1基因在肝脏、肾脏、肺内均有表达。对腹腔肿胀的转基因阳性1号鼠解剖发现肝脏、脾脏明显增大,胚胎发育异常。结论成功建立Dicer1基因表达的转基因小鼠模型,该模型为进一步研究DICER1基因功能及miRNA的表达及功能等奠定基础。     

Transient expression of hepatitis B virus surface antigen (HBsAg) gene in monkey cells by a SV40-based virus vector

Summary We have constructed a recombinant SV40-based vector carrying the S gene coding for the hepatitis B virus surface antigen (HBsAg). This vector replicates as an episome in monkey COS7 cells, producing high levels of hepatitis B virus surface antigen (HBsAg), which is liberated in the cell medium, probably as a membrane vesicule. The vector also carries the SV40-late genes and produces recombinant viruses. These viruses were used to infect fresh cell culture, with detection of HBsAg in the medium. Thus, this virus vector can efficiently transduce the gene for HBsAg.     

Seroepidemiologic study of adult T-cell leukemia virus (ATLV) and hepatitis B virus infection in Okinawa, Japan

A total of 2,283 serum samples were collected from healthy subjects in three islands of the Yaeyama district of Okinawa, Japan. These sera were tested for the presence of hepatitis B surface antigen (HBsAg), for antibody to hepatitis B core antigen (anti-HBc), and for antibody to adult T-cell leukemia-associated antigen (anti-ATLA). Correlation between hepatitis B virus infection and adult T-cell leukemia virus (ATLV) infection was determined by using the prevalence rates for three virus markers. Overall prevalence of HBsAg, anti-HBc and anti-ATLA was 6.5%, 57.4%, and 17.9%, respectively. Age-specific prevalence of anti-HBc and anti-ATLA increased with age, but that of HBsAg did not. Sex-specific prevalence of HBsAg was significantly higher in males than in females, but that of anti-ATLA was significantly higher in females than in males. Statistical analysis revealed that prevalence of anti-ATLA was significantly higher in HBsAg-positive persons and HBsAg-negative/anti-HBc-positive persons than in those negative for HBsAg and anti-HBc. These data suggest that hepatitis B virus-infected persons have a significantly higher chance of adult T-cell leukemia virus infection than those without hepatitis B virus infection in the area studied.     

Hybrid hepatitis B virus nucleocapsid bearing an immunodominant region from hepatitis B virus surface antigen.

A hepatitis B core antigen (HBcAg) gene bearing the 39-amino-acid-long domain A of hepatitis B surface antigen (HBsAg) within the HBcAg immunodominant loop has been constructed and expressed in Escherichia coli. Chimeric capsids demonstrated HBs but not HBc antigenicity and elicited in mice B-cell and T-cell responses against native HBcAg and HBsAg.     

Hepatitis B virus DNA and e antigen in serum from blood donors in the United Kingdom positive for hepatitis B surface antigen.

Serum samples from 214 blood donors in the United Kingdom who were carriers of hepatitis B surface antigen (HBsAg) were examined for hepatitis B virus deoxyribonucleic acid (DNA) by DNA:DNA hybridisation and for hepatitis B e antigen (HBeAg) and its antibody. One fifth of the donors carried infectious virus in their circulation. The presence of hepatitis B virus DNA correlated well with that of HBeAg, although hepatitis B virus DNA was found in five serum samples that were negative for HBeAg. It is concluded that analysis of serum samples for hepatitis B virus DNA by hybridisation should be the method of choice for determining whether carriers of HBsAg are infectious.     

Liver enzyme concentrations as measure of possible infectivity in chronic asymptomatic carriers of hepatitis B.

Fifty-two British-born blood donors who were chronic carriers of hepatitis B surface antigen (HBsAg) were tested for the presence of hepatitis B e antigen (HBeAg) and antibody to HBeAg by an immunoradiometric assay. The presence of HBeAg was closely associated with a slight rise in serum liver enzyme concentrations, a high HBsAg titre, and male sex. We suggest that the finding of persistently raised serum liver enzyme concentrations in an asymptomatic HBsAg carrier might be useful as a likely indicator of HBeAg and high infectivity.     

一种新的乙型肝炎病毒表面抗原结合蛋白的筛选、表达及其生物学活性的初步研究

为了研究乙肝病毒侵染肝细胞过程中的功能蛋白 ,通过印迹免疫分析技术从人肝cDNA噬菌体表达库中筛选出一株编码乙肝表面抗原结合蛋白 (hepatitisBsurfaceantigenbindingprotein ,HBsAg BP)的cDNA克隆 .基因测序结果表明 ,该cDNA具有独立的开放阅读框架 ,编码 1个由 344个氨基酸残基构成的可溶性蛋白分子 ,属于免疫球蛋白超家族成员 .将该基因克隆到原核表达载体pTriplEx后 ,在E .coliXL1 Blue菌株中获得 4 4kD的重组蛋白 .重组蛋白经Western印迹和ELISA实验证明具有与乙肝表面抗原特异性结合的能力 .进一步经流式细胞仪实验显示 ,在纯化的重组蛋白存在的情况下 ,天然的HBsAg与肝细胞株HepG2的亲和力显著增高 .结果显示 ,该乙肝表面抗原结合蛋白可能是介导乙肝病毒对肝细胞亲和侵染的可溶性辅助受体 .     

Detection of core antibody in hepatitis B infection.

Hepatitis B core antigen (HBcAg) is found on the decoated Dane particle and on a morphologically similar particle detected mainly in the nucleus of hepatocytes of patients with hepatitis B. HBcAg prepared from the liver of a chimpanzee infected with hepatitis B virus was used to test human serum for core antibody (anti-HBc) by complement fixation. Anti-HBc was found in serum collected from patients with hepatitis B in both the acute and convalescent stages, from carriers of hepatitis B surface antigen (HBsAg) and from patients with chronic liver or renal disease who were carriers of HBsAg. It was not found in patients with hepatitis A or infectious mononucleosis, or in healthy persons who were not carriers of HBsAg.     

IgM antibody against hepatitis B core antigen (IgM anti-HBc): diagnostic and prognostic significance in acute HBsAg positive hepatitis.

IgM antibody against hepatitis B core antigen (IgM anti-HBc), a marker of recent hepatitis B virus infection, was sought by radioimmunoassay in sera diluted 1/4000 from 376 patients presenting to four centres in Italy with acute, apparently type B hepatitis (hepatitis B surface antigen (HBsAg) positive). In 320 patients (85%) a positive IgM anti-HBc test result confirmed that hepatitis was due to primary infection with hepatitis B virus. In the remaining 56 patients absence of the IgM marker indicated that they were previously unrecognised long term carriers of HBsAg. Further serum analysis often showed delta infection and occasionally hepatitis A or cytomegalovirus infection as the true cause of their illness. After six to eight months circulating HBsAg persisted in 38 of 45 patients (84%) without IgM anti-HBc but in only six of 150 patients (4%) with the IgM antibody (p less than 0.0001). A negative IgM anti-HBc test result in patients with acute HBsAg positive hepatitis points to a factor other than hepatitis B virus as the cause of the liver damage and predicts the carriage of HBsAg.     

Genetic vaccination. Perspectives for the prevention and treatment of hepatitis B

Genetic vaccination by intramuscular injection of a plasmid vector encoding the hepatitis B virus surface antigen (HBsAg) induces antibodies in mice that are specific for the hepatitis B virus envelope proteins. The antibody titres were very high and remained constant for more than 6 months after a single injection. Transgenic (Tg) mice that constitutively express the HBsAg in the liver were used as a model for hepatitis B virus chronic carriers. Intramuscular injection of a plasmid encoding the HBsAg in Tg mice resulted in the complete clearance of circulating HBsAg and in the long-term control of transgene mRNA expression in hepatocytes. Genetic vaccination appears therefore as a promising method for both prevention and treatment of hepatitis B.     

Antibody to hepatitis B core antigen in chronic active hepatitis.

Antibody to hepatitis B core antigen (anti-HBc), which has been assumed to be a more sensitive indicator of hepatitis B virus replication than hepatitis B surface antigen (HBsAg), was detected in the sera of 26 of our 65 patients with HBsAg-negative chronic active hepatitis. Thus despite the absence of HBsAg the liver disease could be the consequence of chronic infection with hepatitis B virus in these patients. They differed, however, from a group of 35 patients with HBsAg-positive hepatitis in being older on average and having less active liver lesions. The two groups could represent either two stages of chronic infection with hepatitis B virus or two types of response to it.